Overall, 102 (49.3%) patients were of female sex, 36 (17.4%) had previously received at least one bDMARD (including an IL-17A inhibitor (5.8%), IL-23p19i (7.7%) or TNF inhibitor (8.2%)), 9 (4.3%) patients had received two prior bDMARDs, and 65 (31.6%) and 24 (11.7%) evaluated patients had enthesitis and dactylitis, respectively. Here, IL17A is linked to enthesitis.